PharmaEngine, Inc.

Taipei Exchange 4162.TWO

PharmaEngine, Inc. Current Liabilities for the year ending December 31, 2023: USD 2.73 M

PharmaEngine, Inc. Current Liabilities is USD 2.73 M for the year ending December 31, 2023, a 6.36% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

PharmaEngine, Inc. Current Liabilities for the year ending December 31, 2022 was USD 2.57 M, a -18.82% change year over year.
PharmaEngine, Inc. Current Liabilities for the year ending December 31, 2021 was USD 3.16 M, a -51.76% change year over year.
PharmaEngine, Inc. Current Liabilities for the year ending December 31, 2020 was USD 6.56 M, a 41.70% change year over year.
PharmaEngine, Inc. Current Liabilities for the year ending December 31, 2019 was USD 4.63 M, a -7.30% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Taipei Exchange: 4162.TWO

PharmaEngine, Inc.

CEO	Mr. Hong-Ren Wang Ph.D.
IPO Date	June 20, 2012
Location	Taiwan
Headquarters	10 Minsheng East Road
Employees	17
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

Key trends

Past 5 years